ADDF and Harrington Discovery Institute Invite Applications for 2018 ADDF-Harrington Scholar Award

March 28, 2018

Category: Initiatives

Harrington Discovery Institute and the Alzheimer’s Drug Discovery Foundation (ADDF) announce a request for proposals for the 2018 ADDF-Harrington Scholar Award. The ADDF-Harrington Scholar Award is designed to accelerate the translation of innovative research that could treat, prevent, slow, or cure people with Alzheimer’s disease, related dementias and cognitive-decline associated with aging.

Applicants have the opportunity to receive:

  • Financial support up to $600,000 over two years
  • Drug development and project management support through Harrington Discovery Institute’s Innovation Support Center

Collaborating for a cure: 

“This is a tremendous opportunity for innovative researchers who seek a cure for Alzheimer’s and other dementias,” said Jonathan Stamler, MD, President, Harrington Discovery Institute and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at University Hospitals and Case Western Reserve University School of Medicine. “The ADDF-Harrington Scholar Award offers a unique combination of drug development expertise and funding to accelerate the most promising discoveries in Alzheimers disease into medicines.” 

“Developing a drug for Alzheimer’s takes significant resources—in terms of both expertise and costs. This partnership was created to give researchers access to more of those resources so they can develop better drugs more rapidly. It has been very successful, and we are excited to continue the partnership,” noted Howard Fillit, MD, Founding Executive Director and Chief Science Officer at the ADDF.

Award criteria:

  • The competition is open to academic investigators at accredited medical centers, research institutions and universities in the United States;
  • Lead investigator must have an MD and/or PhD or equivalent;
  • Proposals should offer creative science or approach to treat, prevent or slow Alzheimer’s disease, other dementias or cognitive-decline associated with aging.

Please note the following dates:

  • Letters of Intent will be accepted through May 25, 2018, 11:59 PM EDT
  • Up to 3 awards will be announced by the end of December
  • Applications must be submitted online at